Prior to the introduction of anti-VEGF agents in clinical practice, CNV formation used to lead to rapid irreversible loss of central vision and legal blindness.[2] Prior to anti-VEGF treatment, vitamin A was administered to treat SFD related nyctalopia.[2,86] Low doses of Vitamin A were not efficient in the treatment of nyctalopia, whereas higher doses induced liver toxicity.[2,86] Hence, Vitamin A has not been widely adopted for the treatment of night blindness associated with SFD. The gene discussed is VEGFA; the disease is Sorsby fundus dystrophy.